See the DrugPatentWatch profile for Defitelio
While specific Defitelio coupons or discount programs are not publicly detailed in the provided information, pharmaceutical manufacturers often offer patient assistance programs for their medications [1]. These programs can help reduce out-of-pocket costs for eligible patients who have commercial insurance and face high co-pays, or for those who are uninsured [1].
What assistance is available for Defitelio costs?
Patients seeking financial assistance for Defitelio should explore manufacturer-sponsored programs. These typically involve an application process and have eligibility requirements based on insurance status and income [1]. It is advisable for patients to inquire directly with the Defitelio manufacturer or their healthcare provider about available support options [1].
How does Defitelio work?
Defitelio (defibrotide sodium) is a novel hemostatic agent used for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), in pediatric and adult patients undergoing hematopoietic stem cell transplantation (HSCT) [2]. It works by normalizing the fibrinolytic system, which is dysregulated in VOD/SOS [2]. Defibrotide is a deoxyribonucleic acid derivative that exhibits antithrombotic and profibrinolytic properties [2]. It is believed to restore the balance between procoagulant and anticoagulant factors, thereby reducing clot formation and promoting clot breakdown [2].
What are the side effects of Defitelio?
Common side effects associated with Defitelio include diarrhea, nausea, vomiting, and hypotension [3]. More serious side effects can involve hypersensitivity reactions and bleeding events [3]. It is crucial for patients to report any adverse reactions to their healthcare provider immediately [3].
What is the recommended dosage for Defitelio?
The recommended dose of Defitelio is 6.25 mg/kg every 6 hours [3]. It is administered intravenously over approximately 30 minutes [3]. The duration of treatment is typically up to 21 days, or until recovery from VOD/SOS [3].
What is Hepatic Veno-Occlusive Disease (VOD)?
Hepatic Veno-Occlusive Disease (VOD), also referred to as sinusoidal obstruction syndrome (SOS), is a serious complication that can occur after myeloablative therapy, often in the context of hematopoietic stem cell transplantation (HSCT) [2]. It is characterized by the obstruction of the hepatic sinusoids and small hepatic veins, leading to liver dysfunction, fluid accumulation in the abdomen, and other organ damage [2]. The pathophysiology involves endothelial damage and subsequent activation of coagulation and fibrinolysis within the liver [2].
What is the regulatory status of Defitelio?
Defitelio received approval from the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of severe VOD/SOS in pediatric and adult patients [2]. It is also approved in the European Union and other countries [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/defitelio/patient-assistance
[2] https://www.rxlist.com/defitelio-drug-market-status.htm
[3] https://www.rxlist.com/defitelio-side-effects-drug-center.htm